Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nomegestrol Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 7/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 7/20 | 1.00 |
| ▸ | AR | P10275 | 7/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nomegestrol Acetate SCHEMBL19760877 | 1.00 | PGR (1.00) | PGRNR3C1ARPDE4DCYP3A4 | |
| Nomegestrol Acetate SCHEMBL8817628 | 1.00 | PGR (1.00) | PGRNR3C1ARPDE4DCYP3A4 | |
| SCHEMBL8626100 | 0.90 | PGR (0.81) | PGRNR3C1ARPDE4DCYP3A4 | |
| SCHEMBL28501809 | 0.90 | PGR (0.81) | PGRNR3C1ARPDE4DCYP3A4 | |
| Amadinone Acetate SCHEMBL282893 | 0.89 | NR3C1 (0.81) | PGRNR3C1ARPDE4DCYP3A4 | |
| Melengestrol Acetate SCHEMBL7759085 | 0.85 | LMNA (0.73) | PGRNR3C1ARPDE4DCYP3A4 | |
| SCHEMBL8769119 | 0.84 | PGR (0.72) | PGRNR3C1ARPDE4DCYP3A4 | |
| Nomegestrol SCHEMBL19760878 | 0.84 | LMNA (0.80) | PGRNR3C1ARPDE4DCYP3A4 | |
| Nomegestrol SCHEMBL139763 | 0.84 | LMNA (0.80) | PGRNR3C1ARPDE4DCYP3A4 | |
| Nomegestrol SCHEMBL6415665 | 0.83 | LMNA (0.79) | PGRNR3C1ARPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2335 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616703-B2 | Methods of contraception using nomegestrol acetate and estradiol | Theramex HQ UK Limited (GB) | 2026-05-05 | — | — | US | claimed |
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | ESTETRA SRL (BE) | 2026-04-02 | — | — | US | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| US-20250360081-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | TRIASTEK INC (CN) | 2025-11-27 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4637777-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | Estetra SRL (BE) | 2025-10-29 | — | — | EP | claimed |
| US-12427114-B2 | Orodispersible dosage unit containing an estetrol component | ESTETRA SRL (BE) | 2025-09-30 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4604932-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2025-08-27 | — | — | EP | claimed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | claimed |
| CN-1083259-C | Transdermal matrix system | LHD LAB HYGIENE DIETETIQUE (FR) | 2002-04-24 | — | — | CN | claimed |
| CN-1301146-A | Topical hormonal composition with systemic effect | THERAMEX (MC) | 2001-06-27 | — | — | CN | claimed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | claimed |
| EP-0613372-B1 | SUBCUTANEOUS IMPLANTS BASED ON NOMEGESTROL DERIVATIVES | THERAMEX (MC) | 2000-12-27 | — | — | EP | claimed |
| CN-1239893-A | Hormonal composition consisting of an estrogenic compound and a progestational compound | THERAMEX (MC) | 1999-12-29 | — | — | CN | claimed |
| US-5955454-A | METHYLATED CYCLODEXTRIN; NONTOXIC, SIDE EFFECT REDUCTION, BIOAVAILABILITY | ADIR ET COMPAGNIE (FR) | 1999-09-21 | — | — | US | claimed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | claimed |
| US-5891867-A | ORAL ADMINISTRATION OF AN ESTROGEN ALONE FOLLOWED BY AN ESTROGEN PROGESTOGEN COMBINATION AND THEN A PLACEBO. | LABORATOIRE THERAMEX (MC) | 1999-04-06 | — | — | US | claimed |
| US-4544555-A | LUTEAL DEFICIENCY HYPERESTROGNIA, HYPERANDROGENIA, SEBORRHEA AND/O | GASTAUD JEAN M | 1985-10-01 | — | — | US | claimed |